Potential 1st-in-class Drug Shows Disease-Modifying Impact in AD
NEW YORK (Reuters Health) – A potential first-in-class anti-OX40 fully human monoclonal antibody has shown promise for treatment of moderate-to-severe
Read moreNEW YORK (Reuters Health) – A potential first-in-class anti-OX40 fully human monoclonal antibody has shown promise for treatment of moderate-to-severe
Read moreThe immunotherapy combination of nivolumab (Opdivo) and ipilimumab (Yervoy) offers a durable, long-term survival benefit over chemotherapy for patients with
Read moreAn investigational gene therapy being developed by PTC Therapeutics is generating hope for children born with aromatic L-amino acid decarboxylase
Read moreNEW YORK (Reuters Health) —Psoriasis patients who are new users of infliximab and adalimumab appear to be at a greater
Read moreBEIJING (Reuters) – Chinese researchers are testing the mixing of COVID-19 vaccine doses developed by CanSino Biologics and a unit
Read moreEditor’s note: Find the latest COVID-19 news and guidance in Medscape’s Coronavirus Resource Center. An estimated 10% to 30% of
Read moreFirst-line tebentafusp significantly improved overall survival (OS) when compared with immunotherapy or chemotherapy in patients with metastatic uveal melanoma in
Read moreUpdated data continue to show significant clinical benefits for patients with unresectable hepatocellular carcinoma (HCC) with the combination of the
Read moreClinicians should be on the lookout for immune-related adverse reactions (irAEs) even after patients have been receiving anti–programmed cell death
Read moreAn experimental immunotherapy that contains a genetically altered version of herpes simplex virus type 1 (HSV-1) was associated with a
Read more